Characteristics of patients receiving immune checkpoint inhibitors (ICI) in ASCO CancerLinQ’s Discovery® Database
This study was conducted to describe the clinical and demographic features of patients receiving ICI treatment along with utilization patterns in real-world settings. This analysis gives insights into patient characteristics and real-world treatment patterns for ICIs. ICIs were used most widely in males, lung cancer patients and patients with advanced disease. These baseline characteristics inform our analyses of ICI use in patients with autoimmune disease, also reported herein.